Elranatamab: Clinical Trials

5 trials of Elranatamab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 1 active not recruiting. 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 35Recruiting 4, Active not recruiting 1

Follow Elranatamab: new trials by email Literature Review of Elranatamab trials Research Report on Elranatamab

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Elranatamab, Lenalidomide (Revlimid®), Daratumumab SC (Darzalex) - Multiple Myeloma, Newly Diagnosed
Phase 3RecruitingIntergroupe Francophone du Myelome8242025-07-092026-09-30
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Elranatamab, Elotuzumab, Pomalidomide - Multiple Myeloma
Phase 3RecruitingPfizer4922024-02-082026-11-12
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma
Phase 3RecruitingPfizer10602022-11-102026-10-27
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Elranatamab, Lenalidomide - Multiple Myeloma
Phase 3Active not recruitingPfizer8542022-03-252026-04-16
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Elranatamab, Daratumumab, Pomalidomide - Multiple Myeloma
Phase 3RecruitingPfizer8932021-10-042026-08-24

Conditions studied

Multiple Myeloma (5)  ·  Hematologic Diseases (1)  ·  Neoplasms, Plasma Cell (1)

Sponsors

Pfizer (4)  ·  Intergroupe Francophone du Myelome (1)

Countries

Belgium (5)  ·  France (5)  ·  Australia (4)  ·  Brazil (4)  ·  Canada (4)  ·  Czechia (4)  ·  Finland (4)  ·  Germany (4)  ·  Greece (4)  ·  Italy (4)  ·  Japan (4)  ·  Netherlands (4)  ·  South Korea (4)  ·  Spain (4)  ·  Taiwan (4)

NIH funding

2023 (3)